Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Assets: 2012-2025

Historic Current Assets for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $2.0 billion.

  • Ptc Therapeutics' Current Assets rose 56.67% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 56.67%. This contributed to the annual value of $1.4 billion for FY2024, which is 12.05% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Current Assets stood at $2.0 billion, which was down 11.66% from $2.3 billion recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Current Assets peaked at $2.3 billion during Q1 2025, and registered a low of $517.3 million during Q3 2022.
  • For the 3-year period, Ptc Therapeutics' Current Assets averaged around $1.3 billion, with its median value being $1.3 billion (2024).
  • In the last 5 years, Ptc Therapeutics' Current Assets slumped by 48.84% in 2022 and then skyrocketed by 137.17% in 2024.
  • Ptc Therapeutics' Current Assets (Quarterly) stood at $954.4 million in 2021, then declined by 27.30% to $693.8 million in 2022, then surged by 75.65% to $1.2 billion in 2023, then grew by 12.05% to $1.4 billion in 2024, then soared by 56.67% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q3 2025, $2.3 billion for Q2 2025, and $2.3 billion during Q1 2025.